DMAC – diamedica therapeutics inc. (US:NASDAQ)
Stock Stats
News
DiaMedica Therapeutics (NASDAQ:DMAC) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
DiaMedica signals revised ReMEDy2 trial timeline and expansion cohort completion for DM199 amid cash runway into 2027 [Seeking Alpha]
DiaMedica Therapeutics Inc. (DMAC) Q3 2025 Earnings Call Transcript [Seeking Alpha]
DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights [Yahoo! Finance]
DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
Form 4 DiaMedica Therapeutics For: Nov 21 Filed by: Parsons James T.
Form 10-Q DiaMedica Therapeutics For: Sep 30
Form 8-K DiaMedica Therapeutics For: Nov 12
Form SCHEDULE 13G/A DiaMedica Therapeutics Filed by: JACINTO RICHARD II
Form 4 DiaMedica Therapeutics For: Aug 11 Filed by: Krop Julie
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.